CDRH third-party program
This article was originally published in The Gray Sheet
Executive Summary
Comments are due by Sept. 1 on the agency's proposal to expand its third-party program to 460 Class II devices for which device-specific guidance does not yet exist (1"The Gray Sheet" June 19, p. 5)
You may also be interested in...
FDA Pilots Expansion Of Third-Party Review To Devices Without Guidance
Only six of the twelve "accredited persons" have reviewed three or more 510(k) applications under the current third-party program, a requirement for participation in FDA's expanded third-party pilot.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.